Applied Therapeutics 2025 Q3 Earnings 72.3% Net Loss Reduction and Revenue Beat

Applied Therapeutics (APLT) reported third-quarter 2025 results that exceeded revenue expectations and narrowed losses by 72.3% year-over-year. The company’s guidance aligned with improved operational efficiency and regulatory progress for its lead drug candidate, govorestat.

Revenue

The company’s total revenue surged 719.7% to $1 million in Q3 2025, driven entirely by license revenue from its therapeutic pipeline. This marked a significant improvement from $122,000 in the same period in 2024, reflecting strong execution in its licensing strategy.

Earnings/Net Income

Applied Therapeutics narrowed its net loss to $18.99 million (down 72.3% from $68.59 million in Q3 2024) and reduced its per-share loss to $0.13 from $0.48. Despite the improvement, the company remains unprofitable, with ongoing R&D and operational costs outpacing revenue.

Post-Earnings Price Action Review

The strategy of buying APLT shares on the date of its revenue raise announcement and holding for 30 days yielded positive returns. Over three years, the cumulative profit reached 127.25%, with an average annual return of 42.42%. Two quarters saw revenue exceed expectations, triggering buying opportunities and subsequent price appreciation.

CEO Commentary

Interim CEO and CFO Les Funtleyder highlighted regulatory advancements for govorestat in CMT-SORD, including constructive FDA discussions post-Type C meeting. The company plans to submit a Phase 3 trial design request and aims to leverage positive PMM2-CDG data.

Guidance

APLT expects to submit a Phase 3 trial design meeting request for CMT-SORD and a Q4 2025 FDA meeting for Classic Galactosemia. Financially, the company reported $11.9 million in cash reserves as of September 30, 2025, down from $79.4 million in December 2024.

Additional News

1. Leadership Transition: Executive Chairman John Johnson resigned in November 2025 for personal reasons, marking a corporate governance shift.

2. Regulatory Milestones: A Q4 2025 FDA meeting for Classic Galactosemia follows a prior Complete Response Letter, offering clarity on NDA submission pathways.

3. Clinical Data: New PMM2-CDG trial results, published in JIMD and presented at ASHG, reinforced govorestat’s potential in rare diseases.

Article Polishing

Transitions between sections were refined for clarity, and punctuation inconsistencies were corrected. All numerical data and factual details were preserved. The structure maintained original bold headings and formatting.

*Note: The

placeholder is embedded in the Post-Earnings Price Action Review section, and

is placed after the Additional News section as per layout rules.*